IL188594A - Anti-ccr7 receptor antibodies for the treatment of cancer - Google Patents

Anti-ccr7 receptor antibodies for the treatment of cancer

Info

Publication number
IL188594A
IL188594A IL188594A IL18859408A IL188594A IL 188594 A IL188594 A IL 188594A IL 188594 A IL188594 A IL 188594A IL 18859408 A IL18859408 A IL 18859408A IL 188594 A IL188594 A IL 188594A
Authority
IL
Israel
Prior art keywords
cells
ccr7
antibody
antibodies
receptor
Prior art date
Application number
IL188594A
Other languages
English (en)
Other versions
IL188594A0 (en
Original Assignee
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Autonoma filed Critical Univ Madrid Autonoma
Publication of IL188594A0 publication Critical patent/IL188594A0/en
Publication of IL188594A publication Critical patent/IL188594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL188594A 2005-07-06 2008-01-03 Anti-ccr7 receptor antibodies for the treatment of cancer IL188594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
PCT/EP2006/006556 WO2007003426A1 (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (2)

Publication Number Publication Date
IL188594A0 IL188594A0 (en) 2008-04-13
IL188594A true IL188594A (en) 2012-02-29

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188594A IL188594A (en) 2005-07-06 2008-01-03 Anti-ccr7 receptor antibodies for the treatment of cancer

Country Status (16)

Country Link
US (1) US8066996B2 (cg-RX-API-DMAC10.html)
EP (1) EP1904102B1 (cg-RX-API-DMAC10.html)
JP (1) JP5249025B2 (cg-RX-API-DMAC10.html)
KR (1) KR20080030655A (cg-RX-API-DMAC10.html)
CN (1) CN101257923A (cg-RX-API-DMAC10.html)
AT (1) ATE453407T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006265281C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0612632A2 (cg-RX-API-DMAC10.html)
CA (1) CA2614080C (cg-RX-API-DMAC10.html)
DE (1) DE602006011466D1 (cg-RX-API-DMAC10.html)
DK (1) DK1904102T3 (cg-RX-API-DMAC10.html)
ES (1) ES2338919T3 (cg-RX-API-DMAC10.html)
IL (1) IL188594A (cg-RX-API-DMAC10.html)
PT (1) PT1904102E (cg-RX-API-DMAC10.html)
RU (1) RU2404808C2 (cg-RX-API-DMAC10.html)
WO (2) WO2007003216A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
WO2009139853A2 (en) * 2008-05-14 2009-11-19 Kim, Eldar Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
JP5801202B2 (ja) * 2009-09-29 2015-10-28 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
JP5315495B2 (ja) * 2010-09-28 2013-10-16 積水化学工業株式会社 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
WO2015147335A1 (ja) * 2014-03-27 2015-10-01 国立大学法人大阪大学 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
KR102663440B1 (ko) * 2015-08-10 2024-05-07 펩맵 비.브이. 인간화된 항-ccr7 리셉터 항체
JP2018530560A (ja) 2015-10-09 2018-10-18 サレプタ セラピューティクス， インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
JP2022514867A (ja) * 2018-12-18 2022-02-16 カタパルト セラピューティクス ビー．ヴイ． 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
ATE382372T1 (de) * 2003-06-11 2008-01-15 Univ Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten

Also Published As

Publication number Publication date
CN101257923A (zh) 2008-09-03
AU2006265281B2 (en) 2012-03-01
BRPI0612632A2 (pt) 2012-01-03
EP1904102B1 (en) 2009-12-30
DK1904102T3 (da) 2010-04-19
ATE453407T1 (de) 2010-01-15
CA2614080A1 (en) 2007-01-11
US8066996B2 (en) 2011-11-29
WO2007003426A1 (en) 2007-01-11
AU2006265281A1 (en) 2007-01-11
JP2008545000A (ja) 2008-12-11
WO2007003216A1 (en) 2007-01-11
US20090123483A1 (en) 2009-05-14
PT1904102E (pt) 2010-03-29
IL188594A0 (en) 2008-04-13
CA2614080C (en) 2014-08-26
EP1904102A1 (en) 2008-04-02
AU2006265281C1 (en) 2012-11-15
KR20080030655A (ko) 2008-04-04
RU2008104420A (ru) 2009-08-20
JP5249025B2 (ja) 2013-07-31
DE602006011466D1 (de) 2010-02-11
ES2338919T3 (es) 2010-05-13
RU2404808C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
KR102048718B1 (ko) 항-cxcr4 항체 및 항체-약물 접합체
KR102338832B1 (ko) Ccr9에 대한 항체 및 그의 적용방법
US8066996B2 (en) Anti-CCR7 receptor antibodies for the treatment of cancer
AU2002236519A1 (en) Methods for the prevention and treatment of cancer using anti-C3B(i) antibodies
JP2010509234A (ja) 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
KR20080031049A (ko) 항-ανβ6 항체 및 이의 용도
WO2003047623A1 (en) Treatment of prostate cancer by inhibitors of ncam2
EP2487189A1 (en) Monoclonal antibodies for treatment of cancer
CN110997724A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
JP2018516996A (ja) Ｂ細胞悪性腫瘍を処置するための手段および方法
CA3130113A1 (en) Antibodies to cell adhesion molecule-related/down-regulated by oncogenes (cdon) and uses thereof
AU2001234925A1 (en) Methods for the prevention and treatment of infections using anti-C3b(i) antibodies
AU2007209787B2 (en) Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
KR20200032162A (ko) 항-bst-1 항체 및 시티딘 유사체를 포함하는 약학적 조합물
CN119677779A (zh) 抗核仁磷蛋白1抗体和抗体缀合物组合治疗

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed